



Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

CytoDyn Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

Sep 9 2019, 6:00 AM EDT

CytoDyn Announces Webcast for its Annual Meeting of Stockholders

Sep 6 2019, 5:00 AM EDT

CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab

Sep 4 2019, 6:00 AM EDT

Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	146.94m
Last Price	\$0.39
52-Week Range	\$0.05 - \$0.64

Investor Relations

Marek Ciszewski, J.D.
T: 630-707-8585
mciszewski@cytodyn.com

09/18/2019 03:27 PM EDT

Management Team

Nader Z. Pourhassan, PhD

Director, President and CEO

Michael D. Mulholland

Chief Financial Officer, Treasurer and Corporate Secretary

Nitya G. Ray, PhD

Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

Brendan Rae, PhD, JD

Senior Vice President of Business Development

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.